Myriad to Announce Fiscal First Quarter 2016 Financial Results on November 3, 2015
October 20 2015 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will
issue financial results for the fiscal first-quarter 2016 and
provide a business update following the close of market on Tuesday,
November 3, 2015.
The Company also will host a conference call at 4:30 p.m. ET on
November 3, 2015 to discuss the financial results. Participating on
the call from Myriad will be Mark C. Capone, president and chief
executive officer and Bryan Riggsbee, chief financial officer.
To listen to the call, interested parties in the United States
may dial 800-706-9302 or +1 303-223-4366 for international callers.
All callers will be asked to reference reservation number
21779749.
The conference call also will be available through a live
webcast at www.myriad.com. A replay of the call will be available
two hours after the end of the call for seven days and may be
accessed by dialing 800-633-8284 within the United States or +1
402-977-9140 for international callers and entering reservation
number 21779749.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad discovers
and commercializes molecular diagnostic tests that; determine the
risk of developing disease, accurately diagnose disease, assess the
risk of disease progression, and guide treatment decisions across
six major medical specialties where high value diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary cancer
markets, diversifying its product portfolio through the
introduction of new products and increasing its international
contribution. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024